ToleriMab (anti-CD80/CD86)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameToleriMab (anti-CD80/CD86)
Drug Alias NameToleriMab (anti-B7.1/B7.2)transplant rejection therapy (Innogenetics)monoclonal antibodies (Innogenetics)MAbs (Innogenetics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCluster of differentiation 80 inhibitorsCluster of differentiation 86 inhibitors
TargetsCluster of differentiation 80Cluster of differentiation 86
Therapy Area/IndicationsRejection of organ transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFujirebio Europe NV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFujirebio Europe NV
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantation

Other Information

ATC CodeN/A
Related LinksN/A